Literature DB >> 32282725

The effect of periodontal bacteria infection on incidence and prognosis of cancer: A systematic review and meta-analysis.

Li Xiao1, Qianyu Zhang1, Yanshuang Peng1, Daqing Wang2, Ying Liu1.   

Abstract

BACKGROUND: Periodontal bacteria is the major pathogens in the oral cavity and the main cause of adult chronic periodontitis, but their association with incidence and prognosis in cancer is controversial. The aim of this study was to evaluate the effect of periodontal bacteria infection on incidence and prognosis of cancer.
METHODS: A systematic literature search of PubMed, Embase, Web of Science, and Cochrane Library databases was performed to obtain 39 studies comprising 7184 participants. The incidence of cancer was evaluated as odd ratios (OR) with a 95% confidence interval (95% CI) using Review Manager 5.2 software. Overall survival, cancer-specific survival and disease-free survival, which were measured as hazard ratios (HR) with a 95% CI using Review Manager 5.2 software.
RESULTS: Our results indicated that periodontal bacteria infection increased the incidence of cancer (OR = 1.25; 95%CI: 1.03-1.52) and was associated with poor overall survival (HR = 1.75; 95% CI: 1.40-2.20), disease-free survival (HR = 2.18; 95%CI: 1.24-3.84) and cancer-specific survival (HR = 1.85, 95%CI: 1.44-2.39). Subgroup analysis indicted that the risk of cancer was associated with Porphyromonas gingivalis (Pg) infection (OR = 2.16; 95%CI: 1.34-3.47) and Prevotella intermedia (Pi) infection (OR = 1.28; 95%CI: 1.01-1.63) but not Tannerella forsythia (Tf) (OR = 1.06; 95%CI: 0.8-1.41), Treponema denticola (Td) (OR = 1.30; 95%CI: 0.99-1.72), Aggregatibacter actinomycetemcomitans (Aa) (OR = 1.00; 95%CI: 0.48-2.08) and Fusobacterium nucleatum (Fn) (OR = 0.61; 95%CI: 0.32-1.16).
CONCLUSION: This meta-analysis revealed periodontal bacteria infection increased the incidence of cancer and predicted poor prognosis of cancer.

Entities:  

Mesh:

Year:  2020        PMID: 32282725      PMCID: PMC7220362          DOI: 10.1097/MD.0000000000019698

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Cancer is the second leading cause of death globally and is estimated to account for 9.6 million death in 2018, according to new data from the world health organization. Epidemiological studies established several well-defined risk factors for cancer, including age, heredity, diet, tobacco use, chronic viral infections, and inflammation. However, the viewpoint that bacterial infections cause cancer has been ignored. Until 1994, Helicobacter pylori, which is defined as a class I carcinogen, was associated with the development of cancer in humans. Since then there has been a growing number of evidence supporting an association between cancer and bacterial infection, including those in the oral cavity. Periodontal disease is one of the most common inflammatory diseases in adults. Periodontal bacteria, one of the most important causes of periodontal disease, which can lead to tooth loss and systemic inflammation, are associated with many systemic disorders such as cardiovascular diseases, diabetes, pulmonary diseases and rheumatoid arthritis. Recently, mounting evidence suggests a causal relationship between periodontal bacteria infections and the development of malignancies. Several periodontal bacteria have been reported to be related with development of cancer, such as Pg and Fn. Furthermore, periodontal bacteria infection has been used as marker to evaluate the prognosis of cancer patients. However, owing to difference in study method, sample size, study population and research region, the effect of periodontal bacteria infections on incidence and prognosis of cancer are unclear. In this study, we performed a systematic review of the available literature on this topic in PubMed, Embase, Web of Science, and the Cochrane Library. Then, we conducted a meta-analysis to determine the incidence and prognosis of periodontal bacteria in cancer, for purpose of addressing controversy.

Methods

Literature search

Articles relevant with the subject were retrieved from PubMed, Embase, Web of Science, and Cochrane Library databases on June 10, 2019. The search strategy was listed as follows: ((((cancer [Title/Abstract]) OR tumor [Title/Abstract]) OR malignancy [Title/Abstract]) OR carcinoma [Title/Abstract]) OR neoplasm [Title/Abstract]) AND (((((Porphyromonas gingivalis [Title/Abstract]) OR Fusobacterium nucleatum [Title/Abstract]) OR Tannerella forsythia [Title/Abstract]) OR Treponema denticola [Title/Abstract]) OR Aggregatibacter actinomycetemcomitans [Title/Abstract]) OR Prevotella intermedia [Title/Abstract]). Two reviewers (L.X. and Q.Y.Z.) inspected all candidate articles independently. Discrepancies were resolved by discussion with the senior authors (DQW and YL).

Inclusion and exclusion criteria

The inclusion criteria were: the diagnosis of cancer was confirmed by pathological examination; Study designs must be prospective or retrospective cohort study. Studies must compare patients with periodontal bacteria infected and periodontal bacteria uninfected; Studies must analyze the cancer incidence, OS, DFS, and CSS in cancer patients; Articles were published as original research. The exclusion criteria were: reviews, meeting abstracts, letters; animal model studies.

Data extraction and quality assessment

Two reviewers (LX and QYZ) independently extracted following data and information from final studies: author, year of publication, types of periodontal bacteria, study country, sample size, survival data, and the tumor location. The enrolled literatures were then qualified by PRISMA checklists (Supplementary Table 1: https://enlol.cn/Supplementary%20Materials/Supplementary%20Table%201.docx). Disagreements were resolved by discussion. Two authors (YSP and LX) assessed the final studies, scored them using the modified Newcastle–Ottawa Scale (NOS) and the scoring system was based on three categories: selection, comparability, and outcome. The full score was 8 points, and a high-quality study in our analysis was defined as a study with ≥7 points. Consensus was reached by discussion with senior reviewers (YL and DQW).

Statistical analysis

Review Manager 5.2 (RevMan 5.2) (Cochrane Collaboration, Denmark) was used to conduct all statistical analyses. Standard Cochran Q test and I 2 statistics were used to identify heterogeneity between the included studies. A value of I 2 statistics >50% and P value < .1 indicated significant heterogeneity, therefore a random effects model was used to calculate the pooled OR, HR, and 95% CI in such cases. Otherwise, a fixed effects model was applied. We used the mean sample size as the boundary between studies with large and small sample sizes. Publication bias was detected with the Begg and Egger regression intercept test by using STATA 12. A 2-tailed P value < .05 was considered statistically significant.

Results

Study characteristics

The process used to select the studies included in this article is summarized in Figure 1. From an initial 1194 potentially relevant articles, the duplicate studies were removed and we screened titles and abstracts of articles. Finally, a total of 18 articles including 39 studies and 7264 participants were enrolled in the meta-analysis. The detailed characteristics of the selected studies are presented in Table 1. The selected articles were published from 2013 to 2018, and all articles were evaluated by the NOS (Supplementary Table 2: https://enlol.cn/Supplementary%20Materials/Supplementary%20Table%202.docx). There were 9, 8, 4, and 3 articles related with incidence, OS, DFS, and, CSS, respectively. Sixteen studies were conducted in Asia, 19 in North America and 3 in Europe. Among the 38 included studies, 10 studies involved patients with Pg infection, 15 with Fn infection, 5 with Tf infection, 3 with Aa infection, 3 with Td in infection and 2 with Pi infection. The sample sizes of the included studies ranged from 80 to 1069. According to the mean of all samples, 12 studies were considered to have a large sample size (n > 467), while 11 had a small sample size (n ≤ 467).
Figure 1

Flow chart of literature search and screening process.

Table 1

Characteristics of included studies.

Flow chart of literature search and screening process. Characteristics of included studies.

Periodontal bacteria and incidence of cancer

Twenty-three studies with 10,736 patients reported the relationship between periodontal bacteria and incidence of cancer (Fig. 2). Periodontal bacteria infection increased the incidence of cancer as much as 1.25 times compared with those no infecting with periodontal bacteria (OR = 1.25, 95%CI: 1.03–1.52, P = .02) although with heterogeneity (I  = 71%, P  < .00001). The subgroup studies consisted of different periodontal bacteria, ethnicity of participants, tumor location, and sample size (Table 2). In our subgroup analysis, individuals whose infected with Pg were at 2.16 times greater risk of developing cancer than those no infecting with Pg (OR = 2.16, 95%CI: 1.34–3.47; P = .001; I  = 79%, P  < .0001). Individuals with Pi infection exhibit increased incidence of cancer (OR = 1.28; 95%CI: 1.01–1.63; P = .04). However, there was no significant relation between the infection of Tf (OR = 1.06, 95%CI: 0.8–1.41, P = .67; I  = 41%, P  = .15), Aa (OR = 1.00, 95%CI: 0.48–2.08, P = 1.00; I  = 80%, P  = .006), Td (OR = 1.30, 95%CI: 0.99–1.72, P = .06; I  = 6%, P  = .35), Fn (OR = 0.61; 95%CI: 0.32–1.16; P = .13; I  = 0%, P  = .68) and incidence of cancer. There was association in Asia (OR = 2.59, 95%CI:1.65–4.05, P < .0001; I  = 94%, P  < .00001) and Caucasian (OR = 1.19, 95%CI:1.03–1.36, P = .02; I  = 44%, P  = .02) between periodontal bacteria infection and incidence of cancer. In the subgroup analysis of tumor location, incidence of cancer was associated with periodontal bacteria infection in OSCC (OR = 10.02, 95%CI:3.11–32.33, P < .0001) but not EC (OR = 1.73, 95%CI:0.80–3.73, P = .17; I  = 82%, P  = .0007), PC (OR = 1.21, 95%CI:0.96–1.53, P = .1; I  = 61%, P  = .02), PLGC (OR = 0.69, 95%CI:0.37–1.29, P = .24; I  = 48%, P  = .12) and CRC (OR = 1.26, 95%CI:1.00–1.57, P = .05; I  = 42%, P  = .12). According to the subgroup analysis of the sample size, periodontal bacteria infection were related to incidence of cancer in large sample size (OR = 1.26, 95%CI:1.08–1.46, P = .003; I  = 46%, P  = .04), but not in small sample size (OR = 1.24, 95%CI:0.73–2.12, P = .42; I 2 = 42%, P  < .00001).
Figure 2

Forest plot of the association between periodontal bacteria infection and incidence of cancer.

Table 2

Subgroup analysis results for periodontal bacteria on incidence of cancer.

Forest plot of the association between periodontal bacteria infection and incidence of cancer. Subgroup analysis results for periodontal bacteria on incidence of cancer.

Periodontal bacteria and OS in cancer

Figure 3A indicates the OS of cancer patients evaluated in 8 studies with 3289 patients. The HR for OS in cancer patients infecting with periodontal bacteria compared with those no infecting with periodontal bacteria was 1.75 times (95% CI: 1.40–2.20, P < .00001). The result revealed periodontal bacteria infection was related to poor OS in cancer. There was little heterogeneity between studies (I  = 0%, P  = .79). The subgroup analysis involved in different periodontal bacteria (Mainly Pg and Fn), ethnicity of participants, tumor location and sample size (Table 3). In the subgroup, both of Pg and Fn infection was correlated with poor OS in cancer (Pg: HR = 4.04, 95% CI: 1.54–10.63, P = .05; Fn: HR = 1.67, 95% CI: 1.32–2.11, P < .0001). There was little heterogeneity between studies (Pg: I  = 0%, P  = .64; Fn: I  = 0%, P  = .99). Periodontal bacteria infection was correlated with poor OS of cancer patients in Asia (HR = 1.90, 95%CI:1.43–2.53, P < .0001; I 2 = 0%, P  = .70) and Caucasian (HR = 1.53, 95%CI:1.05–2.23, P = .03; I  = 0%, P  = .77). In the subgroup of tumor location, there were consistent findings in EC (HR = 2.13, 95%CI:1.36–3.35, P = .0010; I  = 15%, P  = .31) and CRC (HR = 1.64, 95%CI:1.26–2.13, P = .0002; I  = 0%, P  = .97). According to the subgroup analysis of sample size, periodontal bacteria infection exhibited a trend of correlation with poor OS in large (HR = 1.53, 95%CI:1.05–2.23, P = .03; I  = 0%, P  = .77) and small sample size (HR = 1.90, 95%CI:1.43–2.53, P < .0001; I  = 0%, P  = .70).
Figure 3

A. Forest plot of the association between periodontal bacteria infection and overall survival in patients with cancer. B. Forest plot of the association between periodontal bacteria infection and DFS and in patients with cancer. C. Forest plot of the association between periodontal bacteria infection and CSS in patients with cancer.

Table 3

Subgroup analysis results for Pg and Fn infection on the prognostic effects of cancer.

A. Forest plot of the association between periodontal bacteria infection and overall survival in patients with cancer. B. Forest plot of the association between periodontal bacteria infection and DFS and in patients with cancer. C. Forest plot of the association between periodontal bacteria infection and CSS in patients with cancer. Subgroup analysis results for Pg and Fn infection on the prognostic effects of cancer.

Periodontal bacteria and DFS in cancer

Figure 3B shows the results of DFS of cancer patients in 5 studies with 1384 patients. The HR for DFS in cancer patients infecting with periodontal bacteria compared with those not periodontal bacteria was 2.18 times (95% CI: 1.24–3.84, P = .007). The result revealed there was significant association between periodontal bacteria infection and poor DFS in cancer. Interstudy heterogeneity was noted (I  = 81%, P  = .0003). The subgroup studies involved in types of periodontal bacteria, ethnicity of participants, tumor location, and sample size (Table 3).

Periodontal bacteria and CSS in cancer

The association of periodontal bacteria infection and DFS in cancer was supplied by 3 studies with 1674 patients (Fig. 3C). Data analysis showed that the periodontal bacteria infection was related to poor CSS (HR = 1.85, 95% CI: 1.44–2.39, P < .00001) without obvious heterogeneity (I  = 0%, P  = .51).

Heterogeneity and sensitivity analysis

There was evidence of significant heterogeneity in incidence of cancer (I  = 71%, P  < .00001) and DFS (I  = 81%, P  = .0003) but not OS (I  = 0%, P  = .79) and CSS (I  = 0%, P  = .51). Subgroup analyses detecting potential sources of heterogeneity indicated that different periodontal bacteria, ethnicity of participants, tumor location, and sample size were not significantly correlated with the heterogeneity in this meta-analysis. We found that Gao 2016 study was the source of heterogeneity in the meta-analysis for incidence of cancer and Oh 2018 for DFS. After removing Gao 2016 and Oh 2018, the heterogeneity among the studies decreased slightly for incidence of cancer (I  = 64%, P  < .0001), but decreased significantly for DFS (I  = 62%, P  = .05), and the result for incidence of cancer (OR = 1.21, 95%CI: 1.02–1.44, P = .03) (Supplementary Fig. 1) and DFS (HR = 2.79, 95%CI: 1.72–4.54, P < .0001) (Supplementary Fig. 2) followed the same trends as those in the previous analysis. We also performed a sensitivity analysis through removing low-quality studies (NOS < 7). The result for incidence of cancer (OR = 1.29, 95%CI: 1.08–1.53, P = .005) (Supplementary Fig. 3), OS (OR = 1.67, 95%CI: 1.28–2.18, P = .0002) (Supplementary Fig. 4), DFS (HR = 2.34, 95%CI: 1.28–4.28, P = .006) (Supplementary Fig. 5) followed the same trends as those in the previous analysis.

Publication bias

The results of the risk of bias assessment are shown in Figure 4A, B. Egger and Begg tests indicated the potential publication bias for incidence (0.092) and prognosis (including OS, DFS, and CSS: 0.624) of cancer. There was no significant publication bias in these studies.
Figure 4

A. Begg funnel plot of publication bias test for incidence in cancer. B. Begg funnel plot of publication bias test for overall survival, disease-free survival, and cancer-specific survival in cancer.

A. Begg funnel plot of publication bias test for incidence in cancer. B. Begg funnel plot of publication bias test for overall survival, disease-free survival, and cancer-specific survival in cancer.

Discussion

There is increasing evidence that bacteria play an important role in tumorigenesis by activating chronic inflammation. Chronic inflammation and infections are increasingly identified as an important epidemiologic and environmental factor in cancer development. There is considerable evidence that proves the interrelationship between bacterial infections and carcinogenesis, such as Helicobacter Pylori for gastric cancer and Fn for CRC. The relationship between periodontal bacteria and inflammation has attracted the attention from researchers due to the potential influence of periodontitis on initiation and/or progression of several systemic diseases, including cancer. Therefore, many recent studies explore the interrelationship between periodontal bacteria, inflammation, and cancer. However, no consensus has been reached on the effects of periodontal bacteria on incidence and prognosis of cancer. In this meta-analysis, 38 studies including 7184 patients were involved, and we summarized the associations between 6 periodontal bacteria and incidence and prognosis of cancer. The infection of 6 periodontal bacteria was found to increase incidence of cancer and the risk of cancer as much as 1.25 times compared with uninfected patients. Further, the infection of 6 periodontal bacteria was a considerable prognostic factor for poor OS, DFS and CSS. However, in our subgroup analysis, infection of Fn had no significant effect on incidence of cancer. According to numerous current study reports, Fn was tightly related to the occurrence and development of gastrointestinal cancer. Moreover, in our subgroup of OS, Fn was associated with poor OS in cancer patients. Because the sample sizes about incidence of cancer are relatively limited, our results require careful interpretation. Subgroup analysis of cancer incidence showed that infection Pg increased risk of cancer as much as 2.16 times compared with uninfected patients. In line with our results, it has been reported that infection Pg was is a significant risk factor for various malignancies including orodigestive cancers, gastrointestinal cancer, and even prostate cancer. Previous study showed that Pg can promote the development of orodigestive cancers by inducing epithelial-to-mesenchymal transition, activating metalloproteinase-9 and interleukin-8 and accelerating cell cycling and suppressing apoptosis. In our results, there was no significant relationship between infection of Tf, Aa, Td, and Fn and incidence of cancer. Previous studies indicated that Tf, Aa, and Td had a positive effect on progression of cancer. It is pity that the number of related studies are limited. A large number of studies focused on the relationship between Pg and Fn infection and incidence and prognosis of cancer, while less attention was paid to the remaining periodontal bacteria, including Tf, Aa, Td, and Pi. Therefore, the number of included studies about Tf, Aa, Td, and Pi are relatively small, which there were only 5 studies on Tf, 3 on An, 3 on Td and 2 on Pi. Numerous studies showed that 6 periodontal bacteria play an equally important role in the incidence and development of periodontitis and are associated with systemic diseases, but the detection rates may be different due to ethnic differences. These results hinted that more studies are needed to determine whether the infection of these periodontal bacteria can influence the incidence of cancer. Subgroup analysis of OS and DFS suggested that infection of Pg and Fn predicted a poor prognosis in cancer patients. Similarly, current study reported that both Pg and Fn had attributes consistent with a role in cancer development and progression. Moreover, there is extensive evidence showing that Pg and Fn are abundant in tumors and activate transduction pathways, such as anti-apoptotic pathway and nuclear factor-κB, leading to poor prognosis of cancer. In addition, the subgroup analysis of tumor location indicated that periodontal bacteria infection was correlated with a poor prognosis in patients with EC and CRC. Recently studies in animals and man have indicated that oral bacteria can influence the prognosis of patients with digestive system cancers including EC and CRC by perpetuating inflammation, regulating the immune system-microbe-tumor axis, affecting metabolism, and altering the tumor microenvironment. Although we have conducted a comprehensive search and systematic analysis of the relevant studies, inevitably, this meta-analysis has the following limitations. Firstly the number of included studies about Aa, Td, and Pi are relatively small. Secondly, the overall heterogeneity was high, so random effects models were required for the analysis. Thirdly, the study populations were all of Asian or Caucasian ethnicity, which may have caused a population selection bias. Last but not least, we did not take into account the effects of oral fungi on periodontal bacteria. The association between oral fungi, especially Candida spp and oral cancer and oral precancerous lesions was reported in previous studies. Candida spp has been reported to interact with individual members of the oral bacterial microbiota, leading to either synergistic or antagonistic relationships. As a result, oral fungi may also regulate tumors indirectly through the interaction with periodontal bacteria.

Conclusion

this meta-analysis suggested that different periodontal bacteria infection correlated with different incidence of cancer: Pg and Pi infection was associated with high incidence of cancer, while there is no obvious relationship between the Tf, Aa, Td and Fn infection and incidence of cancer. Furthermore, our study revealed that the infection of periodontal bacteria, mainly Pg and Fn, predicted poor OS, DFS, and CSS in cancer patients. Our meta-analysis hinted that improvement of oral hygiene and treatment of periodontal disease should also be taken into consideration in the prevention and treatment strategies for cancer.

Acknowledgments

We are grateful to all researchers of enrolled studies.

Author contributions

Two reviewers (L.X and Q.Y.Z) independently extracted data and information from final studies. Two authors (Y.S.P &L.X) assessed the final studies, scored them using the NOS and consensus was reached by discussion with senior reviewers (Y.L. and D.Q.W.).
  58 in total

Review 1.  Some risk factors for the progression of periodontal disease.

Authors:  U Skaleric; M Kovac-Kavcic
Journal:  J Int Acad Periodontol       Date:  2000-01

2.  Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.

Authors:  Yongzhi Yang; Wenhao Weng; Junjie Peng; Leiming Hong; Lei Yang; Yuji Toiyama; Renyuan Gao; Minfeng Liu; Mingming Yin; Cheng Pan; Hao Li; Bomin Guo; Qingchao Zhu; Qing Wei; Mary-Pat Moyer; Ping Wang; Sanjun Cai; Ajay Goel; Huanlong Qin; Yanlei Ma
Journal:  Gastroenterology       Date:  2016-11-19       Impact factor: 22.682

3.  Study of virulence factor of Candida species in oral lesions and its association with potentially malignant and malignant lesions.

Authors:  Graciela Del Valle Castillo; Silvia López de Blanc; Claudia Elena Sotomayor; Ana Isabel Azcurra
Journal:  Arch Oral Biol       Date:  2018-02-19       Impact factor: 2.633

4.  Microbiological Distribution of Six Periodontal Pathogens Between Untreated Italian and Dutch Periodontal Patients.

Authors:  Marco Montevecchi; Fabio Angelini; Vittorio Checchi; Maria Rosaria Gatto; Luigi Checchi
Journal:  Oral Health Prev Dent       Date:  2016       Impact factor: 1.256

5.  Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum.

Authors:  Li Liu; Fred K Tabung; Xuehong Zhang; Jonathan A Nowak; Zhi Rong Qian; Tsuyoshi Hamada; Daniel Nevo; Susan Bullman; Kosuke Mima; Keisuke Kosumi; Annacarolina da Silva; Mingyang Song; Yin Cao; Tyler S Twombly; Yan Shi; Hongli Liu; Mancang Gu; Hideo Koh; Wanwan Li; Chunxia Du; Yang Chen; Chenxi Li; Wenbin Li; Raaj S Mehta; Kana Wu; Molin Wang; Aleksander D Kostic; Marios Giannakis; Wendy S Garrett; Curtis Hutthenhower; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino; Edward L Giovannucci
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

6.  Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis.

Authors:  Kensuke Yamamura; Yoshifumi Baba; Shigeki Nakagawa; Kosuke Mima; Keisuke Miyake; Kenichi Nakamura; Hiroshi Sawayama; Koichi Kinoshita; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yoichi Yamashita; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Clin Cancer Res       Date:  2016-10-21       Impact factor: 12.531

7.  Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients.

Authors:  Xuebing Yan; Liguo Liu; Hao Li; Huanlong Qin; Zhenliang Sun
Journal:  Onco Targets Ther       Date:  2017-10-17       Impact factor: 4.147

8.  Aggregatibacter actinomycetemcomitans mediates protection of Porphyromonas gingivalis from Streptococcus sanguinis hydrogen peroxide production in multi-species biofilms.

Authors:  Bin Zhu; Lorna C Macleod; Eric Newsome; Jinlin Liu; Ping Xu
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

9.  Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity.

Authors:  Xiaohang Long; Chi Chun Wong; Li Tong; Eagle S H Chu; Chun Ho Szeto; Minne Y Y Go; Olabisi Oluwabukola Coker; Anthony W H Chan; Francis K L Chan; Joseph J Y Sung; Jun Yu
Journal:  Nat Microbiol       Date:  2019-09-09       Impact factor: 17.745

Review 10.  Candida spp./Bacteria Mixed Biofilms.

Authors:  Maria Elisa Rodrigues; Fernanda Gomes; Célia F Rodrigues
Journal:  J Fungi (Basel)       Date:  2019-12-20
View more
  8 in total

Review 1.  The pathogenic oral-gut-liver axis: new understandings and clinical implications.

Authors:  Jin Imai; Sho Kitamoto; Nobuhiko Kamada
Journal:  Expert Rev Clin Immunol       Date:  2021-06-08       Impact factor: 5.124

Review 2.  Oral Microbiota-A New Frontier in the Pathogenesis and Management of Head and Neck Cancers.

Authors:  Marjut Metsäniitty; Shrabon Hasnat; Tuula Salo; Abdelhakim Salem
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

3.  Low level of antibodies to the oral bacterium Tannerella forsythia predicts bladder cancers and Treponema denticola predicts colon and bladder cancers: A prospective cohort study.

Authors:  Lise Lund Håheim; Dag S Thelle; Kjersti S Rønningen; Ingar Olsen; Per E Schwarze
Journal:  PLoS One       Date:  2022-08-22       Impact factor: 3.752

Review 4.  The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis.

Authors:  Yilin Li; Rui Guo; Patrick Kwabena Oduro; Tongke Sun; Hao Chen; Yating Yi; Weiqian Zeng; Qilong Wang; Ling Leng; Long Yang; Jun Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-18       Impact factor: 6.073

Review 5.  The Oral Microbiome and Cancer.

Authors:  Muhammad Irfan; Renata Zoraida Rizental Delgado; Jorge Frias-Lopez
Journal:  Front Immunol       Date:  2020-10-23       Impact factor: 7.561

Review 6.  Bacterial-Viral Interactions in Human Orodigestive and Female Genital Tract Cancers: A Summary of Epidemiologic and Laboratory Evidence.

Authors:  Ikuko Kato; Jilei Zhang; Jun Sun
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

7.  Periodontal Diseases and COVID-19: A Scoping Review.

Authors:  Lisa Basso; Doriane Chacun; Kadiatou Sy; Brigitte Grosgogeat; Kerstin Gritsch
Journal:  Eur J Dent       Date:  2021-09-09

Review 8.  Oral Microbiome: Getting to Know and Befriend Neighbors, a Biological Approach.

Authors:  Cecilia Bacali; Romana Vulturar; Smaranda Buduru; Angela Cozma; Adriana Fodor; Adina Chiș; Ondine Lucaciu; Laura Damian; Mirela Liliana Moldovan
Journal:  Biomedicines       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.